

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptacmb1647

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS	3	JAN 25	Annual Reload of MEDLINE database
NEWS	4	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS	5	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS	6	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS	7	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS	8	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS	9	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS	10	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS	11	APR 02	DWPI: New display format ALLSTR available
NEWS	12	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS	13	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS	14	APR 07	CA/CAPLUS CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS	15	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAPLUS
NEWS	16	APR 07	MEDLINE Coverage Is Extended Back to 1947

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:27:14 ON 06 MAY 2010

=> file medline biosis caplus embase  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.22	0.22

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 10:27:33 ON 06 MAY 2010

FILE 'BIOSIS' ENTERED AT 10:27:33 ON 06 MAY 2010

Copyright (c) 2010 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 10:27:33 ON 06 MAY 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:27:33 ON 06 MAY 2010

Copyright (c) 2010 Elsevier B.V. All rights reserved.

=> s Hruska K?/AU

L1 1433 HRUSKA K?/AU

=> s l1 and (morphogen and ACE(w)inhibitor)

L2 1 L1 AND (MORPHOGEN AND ACE(W) INHIBITOR)

=> McCartney J?/AU

MCCARTNEY IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s McCartney J?/AU

L3 662 MCCARTNEY J?/AU

=> s l3 and (morphogen and ACE(w)inhibitor)

L4 1 L3 AND (MORPHOGEN AND ACE(W) INHIBITOR)

=> s Charette M?/AU

L5 325 CHARETTE M?/AU

=> s l5 and (morphogen and ACE(w)inhibitor)

L6 1 L5 AND (MORPHOGEN AND ACE(W) INHIBITOR)

=> dis his

(FILE 'HOME' ENTERED AT 10:27:14 ON 06 MAY 2010)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 10:27:33 ON 06 MAY 2010

L1 1433 S HRUSKA K?/AU

L2 1 S L1 AND (MORPHOGEN AND ACE(W) INHIBITOR)

L3 662 S MCCARTNEY J?/AU

L4 1 S L3 AND (MORPHOGEN AND ACE(W) INHIBITOR)

L5 325 S CHARETTE M?/AU

L6 1 S L5 AND (MORPHOGEN AND ACE(W) INHIBITOR)

=> dis ibib abs l2

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:203626 CAPLUS

DOCUMENT NUMBER: 140:247061

TITLE: Conjoint administration of morphogens and

INVENTOR(S): ACE inhibitors in treatment of  
 chronic renal failure  
 Charette, Marc F.; Hruska, Keith A.;  
 McCartney, John  
 PATENT ASSIGNEE(S): Curis, Inc., USA; Washington University in St. Louis;  
 Barnes-Jewish Hospital  
 SOURCE: PCT Int. Appl., 295 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019876	A2	20040311	WO 2003-US26923	20030828
WO 2004019876	A3	20060323		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497048	A1	20040311	CA 2003-2497048	20030828
AU 2003268219	A1	20040319	AU 2003-268219	20030828
AU 2003268219	B2	20090924		
EP 1578360	A2	20050928	EP 2003-749170	20030828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050272649	A1	20051208	US 2003-650326	20030828
JP 2006516020	T	20060615	JP 2004-531612	20030828
AU 2009250981	A1	20100114	AU 2009-250981	20091216
PRIORITY APPLN. INFO.:				
			US 2002-406431P	P 20020828
			AU 2003-268219	A3 20030828
			WO 2003-US26923	W 20030828

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides reagents and methods for the treatment, and  
 pharmaceuticals for use in the prevention and/or treatment, of chronic  
 renal failure and other renal disorders in subjects (particularly  
 mammalian subjects) renal replacement therapy. The methods involve the  
 conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors  
 or Angiotensin II Receptor Antagonists (AIIRAs) with one or more OP/BMP  
 family of proteins (morphogens, or inducers of  
 morphogens, or agonists of the corresponding morphogen  
 receptors, etc.). The invention also provides methods for implantation of  
 renal cells induced with the conjoint administration of ACE  
 inhibitors or AIIRAs with those morphogens.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
 (3 CITINGS)

=> dis his

(FILE 'HOME' ENTERED AT 10:27:14 ON 06 MAY 2010)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 10:27:33 ON 06 MAY 2010

L1 1433 S HRUSKA K?/AU

L2 1 S L1 AND (MORPHOGEN AND ACE(W)INHIBITOR)

L3 662 S MCCARTNEY J?/AU  
 L4 1 S L3 AND (MORPHOGEN AND ACE(W)INHIBITOR)  
 L5 325 S CHARETTE M?/AU  
 L6 1 S L5 AND (MORPHOGEN AND ACE(W)INHIBITOR)

=> dis ibib abs l4

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN  
 ACCESSION NUMBER: 2004:203626 CAPLUS  
 DOCUMENT NUMBER: 140:247061  
 TITLE: Conjoint administration of morphogens and  
 ACE inhibitors in treatment of  
 chronic renal failure  
 INVENTOR(S): Charette, Marc F.; Hruska, Keith A.; McCartney,  
 John  
 PATENT ASSIGNEE(S): Curis, Inc., USA; Washington University in St. Louis;  
 Barnes-Jewish Hospital  
 SOURCE: PCT Int. Appl., 295 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019876	A2	20040311	WO 2003-US26923	20030828
WO 2004019876	A3	20060323		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2497048	A1	20040311	CA 2003-2497048	20030828
AU 2003268219	A1	20040319	AU 2003-268219	20030828
AU 2003268219	B2	20090924		
EP 1578360	A2	20050928	EP 2003-749170	20030828
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 20050272649	A1	20051208	US 2003-650326	20030828
JP 2006516020	T	20060615	JP 2004-531612	20030828
AU 2009250981	A1	20100114	AU 2009-250981	20091216
PRIORITY APPLN. INFO.:			US 2002-406431P	P 20020828
			AU 2003-268219	A3 20030828
			WO 2003-US26923	W 20030828

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and/or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIRAs) with one or more OP/BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIRAs with those morphogens.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

=> dis ibib abs 16

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 2004:203626 CAPLUS  
DOCUMENT NUMBER: 140:247061  
TITLE: Conjoint administration of morphogens and  
ACE inhibitors in treatment of  
chronic renal failure  
INVENTOR(S): Charette, Marc F.; Hruska, Keith A.;  
McCartney, John  
PATENT ASSIGNEE(S): Curis, Inc., USA; Washington University in St. Louis;  
Barnes-Jewish Hospital  
SOURCE: PCT Int. Appl., 295 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019876	A2	20040311	WO 2003-US26923	20030828
WO 2004019876	A3	20060323		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2497048	A1	20040311	CA 2003-2497048	20030828
AU 2003268219	A1	20040319	AU 2003-268219	20030828
AU 2003268219	B2	20090924		
EP 1578360	A2	20050928	EP 2003-749170	20030828
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 20050272649	A1	20051208	US 2003-650326	20030828
JP 2006516020	T	20060615	JP 2004-531612	20030828
AU 2009250981	A1	20100114	AU 2009-250981	20091216
PRIORITY APPLN. INFO.:			US 2002-406431P	P 20020828
			AU 2003-268219	A3 20030828
			WO 2003-US26923	W 20030828

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and/or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIRAs) with one or more OP/BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIRAs with those morphogens.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD

(3 CITINGS)

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
LOGOFF? (Y)/N/HOLD:y

(FILE 'HOME' ENTERED AT 10:27:14 ON 06 MAY 2010)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 10:27:33 ON 06 MAY 2010

L1	1433	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	HRUSKA K?/AU
L2	1	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	L1 AND (MORPHOGEN AND ACE(W) INHIBITOR)
L3	662	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	MCCARTNEY J?/AU
L4	1	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	L3 AND (MORPHOGEN AND ACE(W) INHIBITOR)
L5	325	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	CHARETTE M?/AU
L6	1	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	L5 AND (MORPHOGEN AND ACE(W) INHIBITOR)
							DIS IBIB ABS L2
							DIS IBIB ABS L4
							DIS IBIB ABS L6

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	41.35	41.57
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.55	-2.55

STN INTERNATIONAL LOGOFF AT 10:30:21 ON 06 MAY 2010